The European Commission has approved Dupixent (dupilumab) for treating moderate to severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 who do not respond adequately to antihistamines and have not previously received anti-IgE treatment. This expands Dupixent's indication in the EU from adults and adolescents to younger children, offering a new targeted therapy option for a condition that causes sudden, debilitating hives and itching. The approval is based on clinical trial data showing significant reduction in urticaria activity and a favorable safety profile. Dupixent is now approved for four chronic inflammatory diseases in children under 12 in the EU, with ongoing studies and regulatory reviews in other regions including the US.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
